The $4B figure for peak annual sales may be too low; as Mavyret did $3.4B (annualized) during 1Q18 despite the fact that it hadn’t yet been rolled out in some major countries such as France.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”